Quick Takeaways
- Rubric Capital Management LP filed SCHEDULE 13G for ARS Pharmaceuticals, Inc. Common Stock, par value $0.0001 per share (SPRY).
- Disclosed ownership: 6.3%.
- Date of event: 31 Dec 2025.
Rubric Capital Management LP - 31 Dec 2025 SCHEDULE 13G Report for ARS Pharmaceuticals, Inc. Common Stock, par value $0.0001 per share (SPRY)
- Filing Manager
- Rubric Capital Management LP
- Reporting Manager
- Rubric Capital Management LP
- Symbol
- SPRY
- Shares outstanding
- 98,883,573 shares
- Disclosed Ownership
- 6,200,000 shares
- Ownership
- 6.3%
- Form type
- SCHEDULE 13G
- Filing time
- 13 Feb 2026, 16:24:54 UTC
- Date of event
- 31 Dec 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"Rubric Capital Management LP disclosed 6.3% ownership in ARS Pharmaceuticals, Inc. Common Stock, par value $0.0001 per share (SPRY) on 31 Dec 2025."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 13 Feb 2026, 16:24.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (2)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Rubric Capital Management LP | 6.3% | 6,200,000 | 0 | 6,200,000 | /s/ Michael Nachmani | Michael Nachmani / Chief Operating Officer | |
| David Rosen | 6.3% | 6,200,000 | 0 | 6,200,000 | /s/ David Rosen | David Rosen / Individually |